mGluR2/3 agonists (AstraZeneca)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamemGluR2/3 agonists (AstraZeneca)
Drug Alias Nameanti-Parkinsonian mGluR2/3 agonists (AstraZeneca)metabotropic glutamate receptor subtype 2/3 agonists (AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMetabotropic glutamate receptor 2 agonistsMetabotropic glutamate receptor 3 agonists
TargetsMetabotropic glutamate receptor 2Metabotropic glutamate receptor 3
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A